The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus
A Study to Observe the Progress of Diabetes Mellitus After 52 or 28 Weeks of HMS5552 Treatment for Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Nanjing First Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Complete HMS5552 treatment and safety visit;
- HbA1c < 8.0% was detected in our laboratory;
- Researchers judged the stability of glucose control based on the data of subjects'visits during HMS5552 treatment and the indicators of our hospital;
- Subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise;
- Willing to sign written informed consent and abide by the research program.
Exclusion Criteria:
- There was a state of illness in the subjects who could not complete the follow-up during the observation period.
- The researchers judged that subjects'compliance with HMS5552 was affected during treatment.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HMS5552 treatment
|
To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: 4 weeks
|
Changes of HbA1c
|
4 weeks
|
|
Fasting glucose
Time Frame: 4 weeks
|
Changes of fasting glucose
|
4 weeks
|
|
Postprandial glucose
Time Frame: 4 weeks
|
Changes of postprandial glucose
|
4 weeks
|
|
C peptide
Time Frame: 4-8 weeks
|
Changes of C peptide
|
4-8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TNF-α
Time Frame: 52 weeks
|
Changes of TNF-α
|
52 weeks
|
|
IL-6
Time Frame: 52 weeks
|
Changes of IL-6
|
52 weeks
|
|
8-iso PGF2α
Time Frame: 52 weeks
|
Changes of 8-iso PGF2α
|
52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KY20190530-01-KS-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.